<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884504</url>
  </required_header>
  <id_info>
    <org_study_id>MDT18052</org_study_id>
    <nct_id>NCT03884504</nct_id>
  </id_info>
  <brief_title>MDT-1118 Japan DT Study</brief_title>
  <acronym>MDT-1118 Japan</acronym>
  <official_title>A Prospective, Multi-Center, Single Arm Clinical Study to Evaluate the MDT-1118 Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the MDT-1118 VAD in a patient population for&#xD;
      destination therapy (long term support) of advanced heart failure. The collected data will be&#xD;
      used to support Japan regulatory application in expanding market approval for destination&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success at 12 months with the following definitions of success and failure</measure>
    <time_frame>Implant to 12 months</time_frame>
    <description>Therapy will be considered a success if, at the end of 12 months in the study:&#xD;
The subject is alive; and&#xD;
The subject has not had a stroke of Modified Rankin Score ≥ 4; and&#xD;
The subject retains the originally implanted device, unless the device was removed due to heart recovery, or the patient is electively transplanted.&#xD;
Therapy will be considered a failure if, within the 12 months in the study:&#xD;
The subject dies; or&#xD;
The subject has a stroke of Modified Rankin Score ≥ 4; or&#xD;
The device malfunctions or fails, requiring exchange, explantation, or urgent transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of all adverse events per INTERMACS definition</measure>
    <time_frame>Implant to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all device malfunctions per INTERMACS definition</measure>
    <time_frame>Implant to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status improvement, as measured by KCCQ</measure>
    <time_frame>Implant to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status improvement, as measured by EuroQol EQ-5D-5L</measure>
    <time_frame>Implant to 12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ventricular Assist Device System</intervention_name>
    <description>Ventricular Assist Device System</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be ≥20 years of age at consent&#xD;
&#xD;
          2. In judgment of body size, body surface area (BSA) and anatomy by Investigator, patient&#xD;
             can be implanted MDT-1118 VAD.&#xD;
&#xD;
          3. Patients with advanced heart failure symptoms (Class IIIB or IV) who are: (patient&#xD;
             must meet one of the following)&#xD;
&#xD;
               1. On optimal medical management, including dietary salt restriction and diuretics,&#xD;
                  for at least 45 out of the last 60 days and are failing to respond; or&#xD;
&#xD;
               2. In Class III or Class IV heart failure for at least 14 days, and dependent on&#xD;
                  intra-aortic balloon pump (IABP) for 7 days and/or inotropes for at least 14 days&#xD;
&#xD;
          4. Left ventricular ejection fraction ≤ 25%&#xD;
&#xD;
          5. LVAD implant is intended as destination therapy&#xD;
&#xD;
          6. Must be able to receive the MDT-1118 VAD&#xD;
&#xD;
          7. Female patients of childbearing potential must agree to use adequate contraceptive&#xD;
             precautions (defined as oral contraceptives, intrauterine devices, surgical&#xD;
             contraceptives or a combination of condom and spermicide) for the duration of the&#xD;
             study&#xD;
&#xD;
          8. The patient has signed the informed consent form and advance directive&#xD;
&#xD;
          9. The patient and the family understand that destination therapy is end-of-life medical&#xD;
             care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with INTERMACS profile 1&#xD;
&#xD;
          2. Existence of any ongoing mechanical circulatory support (MCS) other than an&#xD;
             intra-aortic balloon pump (IABP)&#xD;
&#xD;
          3. Prior cardiac transplant&#xD;
&#xD;
          4. History of confirmed, untreated abdominal/ thoracic aortic aneurysm &gt; 5 cm, or cardiac&#xD;
             aneurysm or intraventricular septum rupture&#xD;
&#xD;
          5. Severe calcification in thoracic aorta&#xD;
&#xD;
          6. Cardiothoracic surgery within 14 days of implantation&#xD;
&#xD;
          7. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave&#xD;
             changes on the ECG, diagnostic biomarkers, ongoing pain and hemodynamic abnormalities&#xD;
             as described in the guidelines published in ACC/AHA 2007 Guidelines for the Management&#xD;
             of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction1&#xD;
&#xD;
          8. Patients eligible for cardiac transplantation&#xD;
&#xD;
          9. On ventilator support for &gt; 72 hours within the four days immediately prior to&#xD;
             implantation&#xD;
&#xD;
         10. Pulmonary embolus within 21 days of implantation as documented by computed tomography&#xD;
             (CT) scan or magnetic resonance imaging (MRI)&#xD;
&#xD;
         11. Symptomatic cerebrovascular disease, stroke within 180 days of implantation or &gt; 80%&#xD;
             stenosis of carotid or cranial vessels&#xD;
&#xD;
         12. Patient seems difficult to control device by oneself due to cerebral disorder&#xD;
&#xD;
         13. History of drug intoxication or alcohol dependence&#xD;
&#xD;
         14. Uncorrected moderate to severe aortic insufficiency. Correction may include repair or&#xD;
             bioprosthesis at the time of implant&#xD;
&#xD;
         15. Severe right ventricular failure as defined by the anticipated need for right&#xD;
             ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO)&#xD;
             at the time of screening or right atrial pressure &gt; 20 mmHg on multiple inotropes or&#xD;
             right ventricular ejection fraction (RVEF) &lt;15% with clinical signs of severe right&#xD;
             heart failure (e.g. Lower extremity edema, ascites or pleural effusions refractory to&#xD;
             treatment with diuretics and two inotropic drugs)&#xD;
&#xD;
         16. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and&#xD;
             laboratory testing, including but not limited to, continued positive cultures,&#xD;
             elevated temperature and white blood cell (WBC) count, hypotension, tachycardia,&#xD;
             generalized malaise despite appropriate antibiotic, antiviral or antifungal treatment&#xD;
&#xD;
         17. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count &lt;&#xD;
             75,000, INR &gt; 2.0 or PTT &gt; 2.5 times control in the absence of anticoagulation&#xD;
             therapy)&#xD;
&#xD;
         18. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or&#xD;
             postoperative therapy that the investigator may administer based upon the patient's&#xD;
             health status&#xD;
&#xD;
         19. Serum creatinine &gt; 3.0 mg/dL within 72 hours of implantation or requiring dialysis or&#xD;
             ultrafiltration&#xD;
&#xD;
         20. Specific liver enzymes [AST (SGOT) and ALT (SGPT] &gt; 3 times upper limit of normal&#xD;
             within 72 hours of implantation&#xD;
&#xD;
         21. A total bilirubin &gt; 3 mg/dL within 72 hours of implantation, or biopsy proven liver&#xD;
             cirrhosis or portal hypertension&#xD;
&#xD;
         22. Patients with a mechanical heart valve&#xD;
&#xD;
         23. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease,&#xD;
             obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or&#xD;
             restrictive cardiomyopathy&#xD;
&#xD;
         24. History of severe COPD or severe restrictive lung disease (e.g FEV1 &lt;50%) or severe&#xD;
             pulmonary hypertension&#xD;
&#xD;
         25. Participation in any other study involving investigational drugs or devices&#xD;
&#xD;
         26. Severe illness, other than heart disease, which would limit survival to &lt; 3 years&#xD;
&#xD;
         27. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities&#xD;
&#xD;
         28. Pregnancy&#xD;
&#xD;
         29. Patient unwilling or unable to comply with study requirements&#xD;
&#xD;
         30. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of&#xD;
             the investigator&#xD;
&#xD;
         31. Inadequate family/social support&#xD;
&#xD;
         32. Systemic disease including collagen disease, insulin dependent severe diabetes or&#xD;
             irreversible multi-organ failure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Tokyo</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Heart Failure</keyword>
  <keyword>Ventricular Assist Device System</keyword>
  <keyword>Destination Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

